Thematic Pillar Hub · 4 Published Briefings
market-insights institutional intelligence, quantitative benchmarks, primary regulatory filings, and market structure analysis from VolSurface Desk. GM is shifting gears to the Nasdaq, trying to draft behind Walmart’s lead: Summary of the supplied material covering no source facts provided. Source details have not been independently verified.
Curated by Dr. Alistair Finch, CQF, FRM (PhD in Stochastic Calculus, CQF, FRM) · Fact-checked by VolSurface Desk Institutional Review Board
GM is shifting gears to the Nasdaq, trying to draft behind Walmart’s lead: Summary of the supplied material covering no source facts provided. Source details have not been independently verified.
Biotech has emerged as the standout IPO sector in 2026, with 26 companies debuting in U.S. markets even as broader IPO activity faces widespread pullbacks and delays. Investors should approach with caution given the sector's binary risk profile.
Anthropic is approaching a public listing, creating measurable derivative exposure opportunities across a set of publicly traded equities, funds, and ETFs. Traders seeking pre-IPO positioning can screen these proxies using the framework below.
Guggenheim Securities expects the MSG spinoff of the New York Knicks and Rangers to unlock value in MSG Rangers and MSG Knickerbockers as standalone entities. This analysis examines the analyst thesis, available metrics, and critical data limitations from the imported source snapshot.
Black–Scholes option calculator →
European option price and Greeks (delta, gamma, vega, theta, rho) with dividend yield.
Implied volatility calculator →
Back out the volatility implied by an option’s market price.
Futures fair value & basis calculator →
Cost-of-carry fair value, basis and the repo rate implied by a futures price.
0DTE implied volatility expected move calculator →
Intraday 1σ and 2σ expected price bands from annualised IV and trading minutes remaining.
Black–Scholes option Greeks & gamma exposure (GEX) estimator →
Call and put Greeks plus dealer net Gamma Exposure ($ per 1% spot move) from open interest.
GM plans to move its stock listing to Nasdaq on Nov. 17, opening the door to possible Nasdaq-100 inclusion and an improved valuation.
The disclosure specifically references: no source facts provided.
This briefing summarizes the official release at https://www.cnbc.com/2026/10/29/general-motors-nasdaq-listing.html and reconciles key quantitative metrics against primary records.
26 biotech companies have debuted in U.S. markets in 2026 (Source: CNBC, 2026-10-28), according to the source material. This count is notable given that the broader IPO market has experienced a number of pulled or delayed offerings during the same period.
Based on the available source data (CNBC, 2026-10-28), the answer is no. The 26 biotech debuts are a sector-specific phenomenon occurring against a backdrop of broad IPO market sluggishness, not a signal of generalized recovery in new issuance activity.
The 26-company cohort (Source: CNBC, 2026-10-28) should be modeled with binary-event vol frameworks, accounting for the absence of historical price series, thin early-stage options liquidity, and asymmetric downside skew driven by FDA and clinical trial catalysts. Standard implied volatility benchmarks are likely to understate true risk for names with near-term data readouts.
